Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 38573938.
- Also identified by DOI 10.1097/JU.0000000000003929.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Our purpose was to determine changes in patient-reported hematuria and urinary symptoms after hyperbaric oxygen (HBO<sub>2</sub>) treatment for radiation cystitis (RC). We analyzed prospectively collected data from the Multicenter Registry for Hyperbaric Oxygen Therapy Consortium accumulated within a week of beginning and ending HBO<sub>2</sub>. Measures included the modified Radiation Therapy Oncology Group (RTOG) Hematuria Scale, Urinary Distress Inventory Short Form, and EuroQol Five Dimension Five Level instrument. RTOG hematuria and Urinary Distress Inventory Short Form scores were compared using the sign test. Logistic regression was used to evaluate characteristics associated with hematuria improvement. A total of 470 registry patients had RC. The median age, number of HBO<sub>2</sub> sessions, and years after radiation were 73 (IQR 12) years, 39 (IQR 10) sessions, and 5 (IQR 8) years, respectively. Eighty-four percent of patients (393/470) had prostate cancer‒related radiation. EuroQol Five Dimension Five Level scores improved from 0.83 (IQR 0.14) to 0.85 (IQR 0.22; <i>P</i> < .001. Three hundred seventy patients had complete RTOG hematuria scores that improved from 2 (IQR 2) to 0 (IQR 2; <i>P</i> < .001. Two hundred forty-six patients had complete Urinary Distress Inventory Short Form ratings that decreased from 33.3 (IQR 44) to 22.2 (IQR 33; <i>P</i> < .001). Regression analysis of those with visible hematuria before HBO<sub>2</sub> showed lower improvement odds associated with higher HBO<sub>2</sub> hematuria scores (odds ratio [OR] 0.44, 95% CI 0.26-0.73; <i>P</i> < .01), a smoking history (OR 0.44, 95% CI 0.21-0.92; <i>P</i> = .03), or a nonprostate cancer history (OR 0.32, 95% CI 0.10-0.99; <i>P</i> = .05). HBO<sub>2</sub> for RC improved reported hematuria, urinary function, and quality of life. Higher baseline hematuria scores, smoking, and nonprostate cancer history were associated with lower odds of hematuria improvement.
Medical subject headings
- Hyperbaric Oxygenation
- Cystitis
- Patient Reported Outcome Measures
- Registries
- Radiation Injuries
- Hematuria